Elevation Oncology, Inc. financial data

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 15 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2,276% % 27%
Debt-to-equity 55% % 2.1%
Return On Equity -74.68% % -25.83%
Return On Assets -48.14% % -24.91%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,215,795 shares 8.4%
Common Stock, Shares, Outstanding 59,223,729 shares 15%
Entity Public Float $135,200,000 USD 156%
Common Stock, Value, Issued $6,000 USD 20%
Weighted Average Number of Shares Outstanding, Basic 59,173,854 shares 14%
Weighted Average Number of Shares Outstanding, Diluted 59,173,854 shares 14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $29,462,000 USD 22%
General and Administrative Expense $16,213,000 USD 12%
Operating Income (Loss) $-49,050,000 USD -27.18%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $-47,951,000 USD -21.96%
Income Tax Expense (Benefit) $38,000 USD 5.6%
Net Income (Loss) Attributable to Parent $-47,989,000 USD -21.95%
Earnings Per Share, Basic -1 USD/shares -9.46%
Earnings Per Share, Diluted -1 USD/shares -9.46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $60,494,000 USD -33.25%
Marketable Securities, Current $20,165,000 USD 50%
Assets, Current $82,194,000 USD -23.82%
Property, Plant and Equipment, Net $29,000 USD -40.82%
Other Assets, Noncurrent $0 USD -100%
Assets $82,223,000 USD -24.54%
Accounts Payable, Current $492,000 USD 13%
Accrued Liabilities, Current $3,744,000 USD 97%
Liabilities, Current $4,236,000 USD 81%
Liabilities $35,489,000 USD 7.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $11,000 USD
Retained Earnings (Accumulated Deficit) $-254,666,000 USD -23.22%
Stockholders' Equity Attributable to Parent $46,734,000 USD -38.36%
Liabilities and Equity $82,223,000 USD -24.54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-12,711,000 USD -32.75%
Net Cash Provided by (Used in) Financing Activities $30,250,000 USD 13,905%
Net Cash Provided by (Used in) Investing Activities $23,758,000 USD 15%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 59,316,859 shares 15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,030,000 USD -73.34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,494,000 USD -33.25%
Interest Paid, Excluding Capitalized Interest, Operating Activities $806,000 USD -9.13%
Deferred Tax Assets, Valuation Allowance $60,330,000 USD 31%
Deferred Tax Assets, Gross $60,334,000 USD 31%
Depreciation $5,000 USD -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $-47,978,000 USD -22.08%
Deferred Tax Assets, Operating Loss Carryforwards $26,500,000 USD 31%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $301,507,000 USD 6.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $4,000 USD 33%
Share-based Payment Arrangement, Expense $4,365,000 USD 57%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%